微信关注
Total item
Cart Subtotal
￥ 0.00 VEGFR
| Catalog No. | Inhibitor Name | VEGFR1 | VEGFR2 | VEGFR3 | Other |
|---|---|---|---|---|---|
| A10001 | Sorafenib Tosylate | ** | Raf-1,B-Raf,B-Raf (V599E) | ||
| A10880 | Sunitinib Malate | * | Kit,FLT3,PDGFRβ | ||
| A10996 | Cabozantinib | *** | **** | *** | c-Met,Kit,Axl |
| A10080 | Ponatinib | **** | Abl,PDGFRα,FGFR1 | ||
| A10103 | Axitinib | **** | **** | **** | PDGFRβ,Kit,PDGFRα |
| A10998 | Foretinib | *** | **** | **** | Met,Tie-2,RON |
| A10963 | Vandetanib | ** | * | ||
| A10137 | Nintedanib | ** | *** | *** | LCK,FLT3,FGFR2 |
| A10250 | Regorafenib | *** | **** | * | RET,Raf-1,Kit |
| A11518 | Pazopanib HCl | *** | ** | * | FGFR,PDGFR,c-Kit |
| A10185 | Cediranib | *** | **** | **** | c-Kit,PDGFRβ,FGFR1 |
| A10703 | PD173074 | * | FGFR1,c-Src | ||
| A11411 | Dovitinib | *** | *** | *** | FLT3,c-Kit,FGFR1 |
| A10025 | Linifanib | **** | **** | * | CSF-1R,FLT3,Kit |
| A10967 | Vatalanib 2HCl | * | ** | * | PDGFRβ,c-Kit,c-Fms |
| A10773 | RAF265 | ** | B-Raf | ||
| A10101 | Tivozanib | ** | *** | ** | EphB2,PDGFRα,PDGFRβ |
| A10608 | Motesanib Diphosphate | **** | **** | *** | Kit,RET,PDGFR |
| A10340 | Lenvatinib | ** | **** | *** | PDGFRβ,FGFR1,PDGFRα |
| A10953 | Orantinib | * | PDGFRβ,FGFR1 | ||
| A10254 | Brivanib | * | ** | FGFR1 | |
| A10587 | MGCD-265 | **** | **** | **** | Met,RON,Tie-2 |
| A10043 | AEE788 | * | * | * | EGFR,HER2/ErbB2,c-Abl |
| A10352 | ENMD-2076 | * | ** | FLT3,RET,Aurora A | |
| A10679 | OSI-930 | *** | *** | CSF-1R,LCK,C-Raf | |
| A10248 | CYC116 | ** | Aurora A,Aurora B,FLT3 | ||
| A10502 | Ki8751 | **** | c-Kit,PDGFRα,FGFR2 | ||
| A10903 | Telatinib | *** | **** | c-Kit,PDGFRα | |
| A11518 | Pazopanib | *** | ** | * | FGFR,PDGFR,c-Kit |
| A10504 | KRN 633 | * | * | * | PDGFRα,c-Kit,BTK |
| A13377 | SAR131675 | ** | |||
| A10198 | Dovitinib Dilactic Acid | *** | *** | *** | FLT3,c-Kit,FGFR1 |
| A11407 | Apatinib | **** | RET,c-Kit,c-Src | ||
| A10154 | BMS-794833 | ** | Met | ||
| A10162 | Brivanib Alaninate | * | ** | FGFR1 | |
| A11396 | Golvatinib | ** | c-Met | ||
| A11954 | ZM 323881 HCl | **** | |||
| A11955 | ZM 306416 | * | Src,Abl | ||
| A16342 | BFH772 | **** | |||
| A11558 | SU5402 | ** | FGFR1,PDGFRβ | ||
| A12437 | Semaxanib | * | |||
| A11244 | LY2874455 | *** | FGFR2,FGFR1,FGFR4 | ||
| A13234 | SKLB1002 | ** | |||
| A14156 | AZD2932 | *** | PDGFRβ,Flt3,c-Kit | ||
| A10893 | Taxifolin (Dihydroquercetin) | ||||
| A11772 | CP-547632 | *** | FGFR | ||
| A12693 | BAW2881 (NVP-BAW2881) | * | *** | * | C-Raf-1,B-RAFV599E,c-Abl |
| A13465 | SKLB610 | * | PDGFR, FGFR2 | ||
| A13819 | TG 100801 | **** | *** | FGFR1, Fyn, Src | |
| A13820 | TG 100572 | **** | *** | FGFR1, Fyn, Src | |
| A14387 | ltiratinib (DCC2701) | *** | MET, TIE2, TRK | ||
| A15073 | E-3810 | *** | ** | *** | FGFR-1, FGFR-2 |
| A15287 | ZM323881 | **** | |||
| A15792 | BMS-817378 | *** | c-Met |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
-
BMS-817378
Catalog No. A15792 -
Altiratinib (DCC2701)
Catalog No. A14387 c-Met/VEGFR 抑制剂Altiratinib (DCC2701)是一种新型的c-MET/TIE-2/VEGFR抑制剂；与体外HGF拮抗剂相比，可有效降低体内的肿瘤负荷并阻断c-MET pTyr（1349）介导的信号传导，细胞生长和迁移。 了解更多 -
NVP-BAW2881
Catalog No. A12693 VEGFR 抑制剂NVP-BAW2881是有效的选择性VEGFR抑制剂（血管内皮生长因子受体酪氨酸激酶抑制剂），IC50 为值9 nM，具有抑制慢性和急性皮肤炎症的作用。 了解更多 -
BFH772
Catalog No. A16342 -
Ningetinib Tosylate
Catalog No. A17039 VEGF and PDGF 抑制剂Ningetinib Tosylate (CT-053Tosylate,DE-120)是一种VEGF和PDGF抑制剂，可能用于治疗与年龄相关的湿性黄斑变性。CAS：1394820-69-9（游离碱）1394820-77-9（甲苯磺酸酯） 了解更多 -
-
最新产品
SU-5408
Catalog No. A17154 -
-
Motesanib Diphosphate (AMG-706)
Catalog No. A10608 VEGFR 抑制剂Motesanib也称为AMG-706，是一种有效的ATP竞争性的VEGFR1/2/3抑制剂，IC50分别为2 nM/3 nM/6 nM；对Kit具有相似的抑制活性，对VEGFR选择性比PDGFR和Ret高10倍。 了解更多 -
Telatinib (BAY 57-9352)
Catalog No. A10903 VEGFR-2 抑制剂Telatinib (BAY 57-9352)是一种口服的血管内皮生长因子受体2和3（VEGFR2/3）和血小板衍生的生长因子受体β酪氨酸激酶的小分子抑制剂，IC50分别为6 nM/4 nM，1 nM和15 nM。 了解更多 -
Dovitinib Dilactic acid (TKI258 Dilactic acid)
Catalog No. A10198 RTK 抑制剂Dovitinib是一种小分子多靶点酪氨酸激酶抑制剂，可抑制通过ZNF198-FGFR1或BCR-FGFR1转化为IL3独立性的Ba / F3细胞，IC50值分别为150 nM和90 nM。 了解更多 -
CYC116 (CYC-116)
Catalog No. A10248 Aurora Kinase 抑制剂CYC116 (CYC-116)是一种有效的Aurora A/B抑制剂，Ki为8.0 nM/9.2 nM，对VEGFR2(Ki为44 nM)作用稍弱。 了解更多 -
Raf265 derivative
Catalog No. A10774 RAF/VEGFR 抑制剂Raf265 derivative是Raf265的衍生物，Raf265是一种口服，高度选择性的RAF和VEGFR激酶抑制剂，IC50为5至10μM。 了解更多 -
BMS-690514
Catalog No. A11263 -
Pazopanib (GW-786034)
Catalog No. A11518 VEGFR 抑制剂Pazopanib (GW-786034)是VEGFR-1，VEGFR-2，VEGFR-3，PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂，可阻止肿瘤生长并抑制血管生成。 了解更多 -
Buflomedil HCl
Catalog No. A11737 -
ZM 323881 hydrochloride
Catalog No. A11954 -
LY 2874455
Catalog No. A11244 -
E-7050 (Golvatinib)
Catalog No. A11396 E-7050 (Golvatinib)是具有潜在抗肿瘤活性的c-Met(肝细胞生长因子受体)和VEGFR-2(血管内皮生长因子受体-2)酪氨酸激酶的口服生物可利用双重激酶抑制剂。 了解更多 -
Vatalanib (PTK787) 2HCl
Catalog No. A10967 VEGFR 抑制剂Vatalanib (PTK787) 2HCl是一种小分子蛋白激酶抑制剂，可抑制抑制所有已知VEGF受体以及血小板衍生的生长因子受体β和c-kit的血管生成，但对VEGFR-2的选择性最高。 了解更多 -
XL647 (Tesevatinib)
Catalog No. A11057 EGFR, HER2 and VEGFR 抑制剂XL647 (Tesevatinib)是一种口服生物可利用的小分子RTK抑制剂，可结合并抑制在肿瘤细胞增殖和肿瘤血管形成中起主要作用的几种酪氨酸受体激酶，包括EGFR，HER2，ERBB2，VEGFR和EphB4。 了解更多 -
BMS-794833
Catalog No. A10154 -
SKLB1002
Catalog No. A13234 -
TG 100801
Catalog No. A13819 -
Brivanib alaninate (BMS-582664)
Catalog No. A10162 -
SAR131675
Catalog No. A13377 -
SKLB610
Catalog No. A13465 -
Fruquintinib
Catalog No. A14393
FILTER BY:
购物选项
- 作用机制
-
- Inhibitor (抑制剂) (89)
- Antagonist (拮抗剂) (1)
- 靶点
ADOOQ 产品质量保证
We promise all products to perform as described.